List of Excipients in Branded Drug VIBATIV

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Theravance Inc	VIBATIV	telavancin hydrochloride	52118-001	HYDROXYPROPYLBETADEX	2027-01-01
Theravance Inc	VIBATIV	telavancin hydrochloride	52118-001	MANNITOL	2027-01-01
Cumberland Pharmaceuticals Inc	VIBATIV	telavancin hydrochloride	66220-315	HYDROCHLORIC ACID	2027-01-01
Cumberland Pharmaceuticals Inc	VIBATIV	telavancin hydrochloride	66220-315	HYDROXYPROPYL BETADEX	2027-01-01

VIBATIV Telavancin Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

VIBATIV (telavancin hydrochloride) is a hospital-use lipoglycopeptide antibiotic supplied as a sterile, preservative-free lyophilized powder in 250 mg and 750 mg single-dose vials. Its commercial opportunity is concentrated in sterile injectable supply, generic or authorized-generic development, hospital formulary access, and formulation improvements that reduce preparation burden. The core excipient platform is relatively simple: mannitol, hydroxypropyl-beta-cyclodextrin, and phosphoric acid support the product's cake structure, solubility, and pH control. The original U.S. regulatory exclusivities have expired, leaving patent scope, injectable manufacturing capability, and clinical differentiation as the principal barriers to competition. [1]

What is VIBATIV and how is it administered?

VIBATIV contains telavancin, a lipoglycopeptide antibacterial derived from vancomycin-related chemistry. The FDA approved VIBATIV in September 2009 for complicated skin and skin-structure infections caused by susceptible Gram-positive bacteria. FDA later approved the drug for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in 2013. [1,2]

The labeled dosage is weight-based:

Parameter	VIBATIV specification
Active ingredient	Telavancin hydrochloride
Approved strengths	250 mg and 750 mg
Dosage form	Lyophilized powder for intravenous infusion
Typical dosage	10 mg/kg intravenously every 24 hours
Infusion duration	At least 60 minutes
Primary administration setting	Hospital and institutional care
U.S. NDA	NDA 022110
Initial U.S. approval	2009
Additional indication	HABP/VABP approval in 2013

Renal impairment requires dose adjustment and monitoring. The label includes renal safety warnings, including nephrotoxicity and the need for renal function assessment. Those warnings affect market access because hospitals may prefer alternatives with simpler renal-management requirements. [1]

What excipients are used in VIBATIV?

The VIBATIV formulation uses excipients that are well suited to an injectable lyophilized product:

Excipient	Formulation function	Commercial significance
Mannitol	Bulking agent and cake-forming material	Supports vial appearance, handling, and lyophilization performance
Hydroxypropyl-beta-cyclodextrin	Solubilizer and stabilizer	Supports aqueous solubility of the lipophilic telavancin molecule
Phosphoric acid	pH adjustment and formulation control	Helps maintain the product's acidic formulation environment

VIBATIV is reconstituted with Sterile Water for Injection and diluted before intravenous administration. The label identifies compatible diluents that include 0.9% sodium chloride injection, 5% dextrose injection, and Lactated Ringer's injection, subject to the applicable preparation instructions. [1]

The formulation's main technical challenge is telavancin's amphiphilic structure. The molecule contains a glycopeptide portion and a lipophilic side chain. That combination creates solubility, aggregation, adsorption, and physical-stability risks. Hydroxypropyl-beta-cyclodextrin is therefore commercially important because it can form inclusion complexes with hydrophobic regions of the active ingredient while maintaining an injectable aqueous product after reconstitution.

How strong is the VIBATIV excipient strategy?

The excipient strategy is technically credible but not highly differentiated from an intellectual-property perspective.

Solubility and physical stability

Hydroxypropyl-beta-cyclodextrin can improve apparent solubility and reduce precipitation risk during reconstitution. Its use also may reduce the need for surfactants or organic cosolvents, which can create additional parenteral safety and compatibility issues.

Mannitol provides a conventional lyophilization platform. It can improve cake structure and facilitate visual inspection of the vial. Its use is less likely than a novel stabilizer or delivery system to support broad formulation exclusivity.

Phosphoric acid provides pH adjustment. In a sterile injectable product, pH control affects chemical stability, reconstitution time, precipitation, and infusion compatibility. It is generally a functional excipient rather than a strong standalone patent differentiator.

Manufacturing performance

The formulation creates several manufacturing control points:

• Cyclodextrin grade and substitution profile
• Active-to-cyclodextrin ratio
• Solution concentration before filling
• Freeze-drying cycle and residual moisture
• Reconstitution time
• Particulate control
• Container-closure integrity
• Compatibility with infusion bags and administration sets

A competing manufacturer would need to reproduce the product's critical quality attributes, not merely match the ingredient list. Lyophilization cycle development is particularly relevant because mannitol crystallization, amorphous content, residual moisture, and cake collapse can affect reconstitution and stability.

Regulatory substitutability

An abbreviated new drug application may permit a generic manufacturer to use different inactive ingredients if the product remains pharmaceutically equivalent and the excipient differences are acceptable for an intravenous drug. A different cyclodextrin system, buffer, or bulking agent could create additional FDA review questions, especially if the change affects safety, infusion compatibility, or reconstitution performance.

A formulation that preserves the VIBATIV excipient system may reduce development risk. A formulation that materially changes the excipient system may create a stronger technical position but could require more comparative testing and a more complex regulatory strategy.

What patents protect VIBATIV?

VIBATIV protection has historically involved several potential layers:

1. Telavancin composition and lipoglycopeptide chemistry.
2. Processes for producing the active pharmaceutical ingredient.
3. Pharmaceutical compositions containing telavancin.
4. Methods for treating bacterial infections.
5. Formulation, dosage, and administration parameters.

The relevant patent record must be evaluated through the FDA Orange Book, USPTO Patent Center, and litigation databases. The Orange Book, rather than commercial product summaries, controls the listed patent and exclusivity information for abbreviated-application purposes. [3]

The key commercial point is timing. VIBATIV was approved in 2009, and its five-year new chemical entity exclusivity would have expired in 2014. Any three-year exclusivity associated with the later indication would also have expired. Accordingly, the principal U.S. entry barriers are no longer FDA exclusivity. They are listed patents, if any remain relevant, manufacturing complexity, clinical risk, and the economics of a small hospital antibiotic market. [1,3]

When does VIBATIV lose exclusivity?

VIBATIV's statutory FDA exclusivity periods have expired.

Exclusivity category	VIBATIV position
New chemical entity exclusivity	Expired
Three-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	Not the primary commercial protection described for VIBATIV's approved indications
Patent exclusivity	Must be assessed against current Orange Book listings and patent expiration data
Pediatric exclusivity	No material current commercial barrier identified in the cited FDA product materials

Patent expiry depends on the specific patent, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension. An investor or generic applicant should not infer patent expiry solely from the 2009 approval date. The FDA's Orange Book patent table and USPTO records remain the operative sources. [3,4]

What is the Orange Book status of VIBATIV?

VIBATIV is an FDA-approved NDA product associated with telavancin hydrochloride and intravenous injection. The Orange Book is the appropriate source for determining whether FDA-listed patents remain attached to the NDA and whether an ANDA applicant would need to make a Paragraph IV certification. [3]

The commercial analysis should distinguish three situations:

• No listed patent remains: an ANDA applicant may pursue a standard certification route.
• A listed patent remains unexpired: the applicant may certify that the patent will not be infringed, is invalid, or is unenforceable.
• A Paragraph IV notice is served: the patent holder may file suit within 45 days, potentially triggering a 30-month stay under the Hatch-Waxman framework. [5]

No biosimilar pathway applies. VIBATIV is a small-molecule drug, not a biologic. Competition would arise through an ANDA, a 505(b)(2) application, an authorized generic, or a separately branded telavancin product.

Which companies are challenging VIBATIV?

The public FDA sources cited here do not establish a current, named Paragraph IV challenger or a current settlement agreement involving VIBATIV. A complete challenger analysis requires matching every current Orange Book listing to ANDA litigation records and FDA approval activity.

Potential competitor categories include:

• Generic injectable manufacturers with lyophilization capacity.
• Contract development and manufacturing organizations.
• Hospital-antibiotic companies with existing infectious-disease sales teams.
• Rights holders pursuing an authorized generic.
• Developers of alternative Gram-positive antibiotics.

The most credible generic threat would come from a company that already manufactures sterile lyophilized antibiotics and has hospital distribution. The product's clinical demand is specialized, so commercial infrastructure may matter more than the basic active-ingredient chemistry.

What formulations are protected by VIBATIV?

The most commercially relevant formulation attributes are the sterile lyophilized powder, single-dose vial, 250 mg and 750 mg strengths, cyclodextrin-enabled solubility, mannitol-based cake formation, and controlled acidic pH. These attributes may be covered by formulation or composition patents if specific claims remain unexpired.

Potential follow-on formulation opportunities include:

Ready-to-use or premixed infusion

A ready-to-use bag could reduce pharmacy preparation steps and reconstitution errors. The product would require a stability package addressing concentration, container materials, adsorption, particulate formation, microbial control, and extended storage.

Faster reconstitution

A formulation with lower reconstitution time could improve hospital workflow. The commercial benefit would be strongest if the product preserves the current dosing and administration route without requiring new clinical efficacy studies.

Lower-volume presentation

A more concentrated formulation could reduce infusion volume and storage requirements. The main risks are local tolerability, precipitation, viscosity, and compatibility with infusion equipment.

Alternative cyclodextrin system

A different cyclodextrin or solubilizer could reduce cost or improve stability. This approach may create formulation intellectual property but could trigger additional FDA scrutiny for parenteral safety and comparative performance.

Pediatric or special-population formulations

The existing product is primarily positioned for adults and hospital use. A lower-strength vial or more flexible concentration could address pediatric or renal-dose preparation, but the market would be limited and would require a clear regulatory and commercial rationale.

What manufacturing and IP barriers affect generic VIBATIV entry?

The active ingredient is only one part of the entry problem. A prospective manufacturer must manage:

• Telavancin synthesis and impurity control.
• Cyclodextrin sourcing and characterization.
• Sterile filtration or aseptic processing.
• Lyophilization cycle transfer.
• Reconstitution and dilution performance.
• Extractables and leachables.
• Particulate and endotoxin specifications.
• Stability under shipping and hospital storage conditions.
• Drug-drug and infusion-line compatibility.

Manufacturing know-how may provide practical protection even when composition patents have expired. A reliable supplier with established sterile injectable operations can shorten development time and reduce batch-failure risk. A company without that platform would face substantial capital and quality-system requirements.

What commercial opportunities exist for VIBATIV excipients?

The strongest opportunities are in enabling products rather than commodity excipient sales.

Cyclodextrin supply

Hydroxypropyl-beta-cyclodextrin suppliers can compete on injectable grade, lot consistency, regulatory documentation, impurity limits, and supply continuity. A supplier that supports formulation development and regulatory filings can capture more value than one selling a generic excipient alone.

Ready-to-use hospital product

A premixed or pharmacy-ready telavancin presentation could compete on preparation time and medication safety. The commercial proposition would depend on proving adequate stability and securing hospital pharmacy adoption.

Authorized generic

An authorized generic could use the established formulation and manufacturing process, reducing clinical and regulatory risk. Its success would depend on the market size, supply reliability, and any contractual rights held by the originator or commercial partner.

Contract manufacturing

A CDMO with sterile lyophilization, cyclodextrin handling, and injectable packaging capabilities could support generic, licensed, or reformulated telavancin products. This is a more immediate opportunity than building a new branded antibiotic franchise.

Combination or stewardship positioning

Telavancin may retain value in selected resistant Gram-positive infections where alternatives are unsuitable. Commercial positioning would need to address renal monitoring, resistance stewardship, and hospital formulary restrictions. The opportunity is specialized rather than broad primary-care volume.

How does VIBATIV compare with competing antibiotics?

Product	Class	Administration	Main commercial advantage	Main limitation
VIBATIV	Lipoglycopeptide	IV, generally once daily	Activity against serious Gram-positive infections	Renal safety and monitoring burden
Vancomycin	Glycopeptide	IV, frequently monitored	Low cost and extensive use	Monitoring, infusion issues, resistance concerns
Dalbavancin	Lipoglycopeptide	Long-acting IV	Very infrequent dosing	High acquisition cost and narrower use cases
Oritavancin	Lipoglycopeptide	Single-dose IV for selected indications	Simplified administration	Limited flexibility and cost considerations
Daptomycin	Lipopeptide	IV, once daily in many uses	Established hospital use	Not suitable for pneumonia
Linezolid	Oxazolidinone	Oral or IV	Oral step-down option	Hematologic and drug-interaction concerns

VIBATIV's commercial position is strongest when once-daily intravenous dosing and Gram-positive activity outweigh renal-risk and cost concerns. It is weaker where oral therapy, long-acting therapy, or lower-cost vancomycin is clinically acceptable.

What is the revenue exposure for VIBATIV?

VIBATIV's revenue exposure is concentrated in institutional infectious-disease purchasing. Demand is affected by:

• Hospital formularies.
• Antimicrobial stewardship policies.
• Resistant Gram-positive infection rates.
• Renal safety perceptions.
• Generic competition.
• Availability of long-acting alternatives.
• Government and hospital procurement pricing.

A reliable current revenue figure cannot be derived from the FDA label or Orange Book. The product's economics should be analyzed through the rights holder's filings, product-level sales disclosures, tender data, and distributor information. A generic entrant would face a limited-volume market but could still achieve attractive economics if it uses an existing sterile injectable platform and avoids major new manufacturing investment.

What patent litigation and settlement risks affect VIBATIV?

Hatch-Waxman risk depends on whether any unexpired patents remain listed against NDA 022110. If an ANDA applicant files a Paragraph IV certification and the patent holder sues within 45 days, FDA approval may be delayed by the statutory 30-month stay, subject to court decisions and statutory exceptions. [5]

A settlement could establish a licensed entry date, authorized-generic arrangement, supply agreement, or other commercial terms. No settlement terms should be assumed without a filed court agreement, FDA record, or company disclosure. For diligence, the decisive documents are the Orange Book listing, ANDA notice letters, district-court docket, and any publicly filed settlement.

Key Takeaways

• VIBATIV is a telavancin hydrochloride sterile lyophilized injectable in 250 mg and 750 mg vials.
• Mannitol supports lyophilization, hydroxypropyl-beta-cyclodextrin supports solubility and stability, and phosphoric acid controls pH.
• FDA exclusivity has expired; remaining entry risk depends on current listed patents, regulatory pathway, and manufacturing capability.
• VIBATIV is a small molecule, so biosimilar competition does not apply.
• The most credible commercial opportunities are generic injectable supply, authorized generic entry, ready-to-use presentations, cyclodextrin supply, and sterile lyophilization services.
• The primary product weaknesses are renal monitoring, hospital-only demand, competition from vancomycin and long-acting agents, and likely pricing pressure from generic entry.
• Formulation improvements that reduce reconstitution time or pharmacy workload have greater commercial potential than minor excipient substitutions.

FAQs

Can VIBATIV be reformulated as a prefilled syringe?

A prefilled syringe would require evidence addressing concentration, stability, viscosity, container compatibility, particulate control, and administration safety. The current lyophilized-vial format does not establish that a prefilled product would be technically or clinically suitable.

Is hydroxypropyl-beta-cyclodextrin essential to telavancin formulation?

It is important to the approved formulation's solubility and stability profile, but an alternative solubilization system could be developed. The alternative would require comparative pharmaceutical and parenteral-safety evaluation.

Can a generic manufacturer use VIBATIV's excipient combination?

A generic manufacturer may be able to use the same excipients if the formulation complies with applicable FDA requirements and does not infringe unexpired patent claims. The final determination depends on the Orange Book, patent claims, and ANDA review.

Does VIBATIV have biosimilar competition?

No. Telavancin is a small-molecule active ingredient. Potential competitors would use an ANDA, 505(b)(2) application, authorized-generic model, or independent NDA pathway.

What is the highest-value formulation improvement for VIBATIV?

A stable pharmacy-ready or premixed intravenous presentation would likely offer the clearest operational value. It could reduce reconstitution steps and preparation time, provided the product maintains acceptable stability, compatibility, and regulatory comparability.

References

1. U.S. Food and Drug Administration. (2023). VIBATIV (telavancin hydrochloride) for injection: Prescribing information.
2. U.S. Food and Drug Administration. (2013). FDA approves VIBATIV for hospital-acquired and ventilator-associated bacterial pneumonia.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Patent and Trademark Office. (2024). Patent Center.
5. U.S. Food and Drug Administration. (2024). The Orange Book and 30-month stays under the Hatch-Waxman Amendments.